AU2017285213B2 - Expression of NKG2D activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells - Google Patents

Expression of NKG2D activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells Download PDF

Info

Publication number
AU2017285213B2
AU2017285213B2 AU2017285213A AU2017285213A AU2017285213B2 AU 2017285213 B2 AU2017285213 B2 AU 2017285213B2 AU 2017285213 A AU2017285213 A AU 2017285213A AU 2017285213 A AU2017285213 A AU 2017285213A AU 2017285213 B2 AU2017285213 B2 AU 2017285213B2
Authority
AU
Australia
Prior art keywords
vector
ulbp3
cell
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017285213A
Other languages
English (en)
Other versions
AU2017285213A1 (en
Inventor
Ndukaku Mgbechinyere AMANKULOR
Joseph C. Glorioso III.
Paola Grandi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of AU2017285213A1 publication Critical patent/AU2017285213A1/en
Application granted granted Critical
Publication of AU2017285213B2 publication Critical patent/AU2017285213B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2017285213A 2016-06-14 2017-06-14 Expression of NKG2D activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells Active AU2017285213B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662350095P 2016-06-14 2016-06-14
US62/350,095 2016-06-14
PCT/US2017/037531 WO2017218689A1 (en) 2016-06-14 2017-06-14 Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells

Publications (2)

Publication Number Publication Date
AU2017285213A1 AU2017285213A1 (en) 2019-01-17
AU2017285213B2 true AU2017285213B2 (en) 2024-05-16

Family

ID=60664263

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017285213A Active AU2017285213B2 (en) 2016-06-14 2017-06-14 Expression of NKG2D activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells

Country Status (9)

Country Link
US (1) US11427625B2 (enExample)
EP (1) EP3468588A4 (enExample)
JP (1) JP7184337B2 (enExample)
CN (1) CN109475613B (enExample)
AU (1) AU2017285213B2 (enExample)
CA (1) CA3027857C (enExample)
MX (1) MX2018015542A (enExample)
NZ (1) NZ749586A (enExample)
WO (1) WO2017218689A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020000993A (es) 2017-07-26 2020-07-22 Oncorus Inc Vectores virales oncolíticos y usos de estos.
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
SG11202101581RA (en) * 2017-08-09 2021-03-30 Ohio State Innovation Foundation Oncolytic virus carrying e-cadherin and uses thereof
US12036256B2 (en) * 2018-04-13 2024-07-16 Regeneron Pharmaceuticals, Inc. Adoptive cellular therapy
EP3874041A1 (en) * 2018-11-01 2021-09-08 Onconetics Pharmaceuticals, Inc. Multi-component vector systems, methods of making, and uses thereof
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
AU2022255538B2 (en) * 2021-04-08 2026-01-22 Immvira Biopharmaceuticals Co., Limited Genetically modified oncolytic herpes simplex virus delivering chemokine and tumor associated/specific antigen
WO2025245495A1 (en) * 2024-05-24 2025-11-27 Cz Biohub Sf, Llc Selective sensitization of cancer cells to elimination by cytotoxic lymphocytes
CN118389408B (zh) * 2024-06-26 2024-11-29 淇嘉科技(苏州)有限公司 炎症性肠病及纤维化体外精准模拟方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999031241A1 (en) 1997-12-17 1999-06-24 Immunex Corporation Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides
JP2005523681A (ja) 2001-10-04 2005-08-11 イミュネックス・コーポレーション Ｕｌ１６結合タンパク質４
US20150165065A1 (en) 2009-12-31 2015-06-18 Avidbiotics Corp. Non-natural mic proteins
WO2012006181A2 (en) 2010-06-29 2012-01-12 Mount Sinai School Of Medicine Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
US20130156808A1 (en) 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
DK3184641T3 (da) * 2013-10-28 2020-08-03 Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education Onkolytisk hsv-vektor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Deng, W et al., 2015. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science, 348(6230), pages 136-139. *
Friese, M.A. et al., 2003. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer research, 63(24), pages 8996-9006. *

Also Published As

Publication number Publication date
EP3468588A1 (en) 2019-04-17
CN109475613A (zh) 2019-03-15
EP3468588A4 (en) 2019-12-11
CN109475613B (zh) 2024-02-20
WO2017218689A1 (en) 2017-12-21
US11427625B2 (en) 2022-08-30
JP7184337B2 (ja) 2022-12-06
NZ749586A (en) 2023-06-30
AU2017285213A1 (en) 2019-01-17
JP2019517815A (ja) 2019-06-27
CA3027857C (en) 2023-07-25
US20200148742A1 (en) 2020-05-14
CA3027857A1 (en) 2017-12-21
MX2018015542A (es) 2019-10-14
WO2017218689A9 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
CA3027857C (en) Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells
US11883448B2 (en) Oncolytic HSV vector
AU2022204729A1 (en) Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
Wang et al. Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity
Grandi et al. Design and application of oncolytic HSV vectors for glioblastoma therapy
JP2020505390A (ja) Ｃｒｉｓｐｒ治療薬を送達するためのウイルスベクターとしてのレンチウイルスおよび非組み込みレンチウイルス
Fu et al. Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity
CN109641020A (zh) 在癌细胞中具有增强复制的hsv载体
TW202305123A (zh) 轉錄及轉譯雙重調節之溶瘤單純疱疹病毒載體
WO2020106566A1 (en) Regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use
JP4369243B2 (ja) 外来性の物質の検出におけるリボザイムの使用
Burton et al. Multi-modal combination gene therapy for malignant glioma using replication-defective HSV vectors
US10370422B2 (en) Membrane-anchoring and apoptosis-inducing fusion protein comprising a fragment of TRAIL and CD40L and encoding polynucleotides
WO2002056917A1 (fr) Virus recombinant capable d'eradiquer de maniere specifique une tumeur associee au virus eb et son procede de construction
TW202102677A (zh) 經修飾腺病毒及含有其之醫藥
Branch TARGETING CANCER THERAPIES
HK1236992A1 (en) Oncolytic hsv vector
HK40036361A (en) Oncolytic hsv vector
HK1236992B (en) Oncolytic hsv vector

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)